Skip to main content
Clinical Trials/NCT05888376
NCT05888376
Completed
N/A

A Post-Market Clinical Performance and Safety Evaluation of GamCath HighFlow Dolphin Protect Catheter

Vantive Health LLC2 sites in 1 country76 target enrollmentDecember 7, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
AKI - Acute Kidney Injury
Sponsor
Vantive Health LLC
Enrollment
76
Locations
2
Primary Endpoint
Reason(s) for Catheter Removal
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of this retrospective chart review is to obtain clinical safety and performance data for the GamCath HighFlow Dolphin Protect Catheter in patients with acute kidney injury, acute renal failure, or chronic kidney disease.

The main questions to answer are:

  1. Duration of catheter use (survival)
  2. Reason(s) for catheter removal

Detailed Description

The objective of this retrospective chart review is to obtain clinical safety and performance data for the GamCath HighFlow Dolphin Protect Catheter related to the duration of use (catheter survival) throughout its lifetime.

Registry
clinicaltrials.gov
Start Date
December 7, 2023
End Date
April 30, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients ≥ 18 years of age at the time of catheter insertion.
  • Patients diagnosed with AKI, ARF, and/or CKD (including end-stage renal disease \[ESRD\]).
  • Patients who required vascular access to perform extracorporeal blood purification using GamCath HighFlow Dolphin Protect Catheter inserted by a physician in the subclavian, jugular, or femoral veins.

Exclusion Criteria

  • Patients who required the GamCath HighFlow Dolphin Protect Catheter for any indication other than extracorporeal blood purification.
  • Patients who had a local infection at the vascular access site prior to catheter insertion.
  • Patients who required surgical intervention (e.g., cutdown procedure) for GamCath HighFlow Dolphin Protect Catheter placement.
  • Patients who had a prior catheter in place at the same vascular access site (i.e., R/L jugular vein, R/L femoral vein, R/L subclavian vein) within the last 7 days.
  • Patients who do not have complete patient records to support the primary endpoint analyses.

Outcomes

Primary Outcomes

Reason(s) for Catheter Removal

Time Frame: Within 72 hours of catheter removal or patient transfer or discharge or death, whichever occurs first, assessed up to 12 weeks

Collect additional real-world use data describing the reason(s) for GamCath HighFlow Dolphin Protect Catheter removal to support PMCF ongoing product safety performance

Catheter Survival

Time Frame: From date of catheter insertion until the date of catheter removal or patient transfer or discharge or death, whichever occurs first, assessed up to 12 weeks

Confirm catheter lifetime related to GamCath HighFlow Dolphin Protect Catheter duration of use to support PMCF ongoing performance data

Secondary Outcomes

  • Adverse Events(From date of catheter insertion until the date of catheter removal or patient transfer or discharge or death, whichever occurs first, assessed up to 12 weeks)

Study Sites (2)

Loading locations...

Similar Trials